ArticleMicrobiology spectrum2026
Discovery and biological evaluation of novel
Lvyin Zheng, Yumei Zhong, Yinyin Li, Peiyi Chen, Nina Cheng, Xiaofeng Hua, Lu Ouyang, Nianhua Luo, Jiayi Shen, Yongdong Li and 1 more
Abstract read
In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Lvyin ZhengJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.ORCID 0000-0002-7916-9890 Yumei ZhongJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Yinyin LiJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Peiyi ChenJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Nina ChengJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Xiaofeng HuaJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Lu OuyangSchool of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi Province, People's Republic of China.
Nianhua LuoSchool of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi Province, People's Republic of China.
Jiayi ShenJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.
Yongdong LiJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.ORCID 0000-0002-8850-0944 Wei GuoJiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi Province, People's Republic of China.ORCID 0000-0002-4456-3927 Funding
Double-Thousand Talents Plan of Jiangxi Province jxsq2019201025Jiangxi Provincial Natural Science Foundation 2023ACB206047Jiangxi Provincial Natural Science Foundation 20242BAB20466Jiangxi Provincial Natural Science Foundation 20242BAB25549National Natural Science Foundation of China 21867001National Natural Science Foundation of China 22167002National Natural Science Foundation of China 22467001National Natural Science Foundation of China 82360675
6 · The paper itselfAbstract
Millions of people in tropical and subtropical regions rely on praziquantel to treat schistosomiasis. The limitations of current treatments and the emerging risk of praziquantel resistance highlight an urgent need for new chemotherapeutic agents. Here, we report the discovery of a novel series of IMPORTANCE: With praziquantel (PZQ) as the sole therapeutic option for schistosomiasis, emerging drug resistance underscores the critical need for new agents. We identified a novel series of
Indexed as
AnthelminticsHydrazinesSchistosoma japonicumSchistosomiasis japonicaSchistosomicidesAnimalsDisease Models, AnimalDrug DiscoveryFemaleMaleMicePraziquantelAnthelminticsHydrazinesPraziquantelSchistosomicidesantischistosomal activitymouse modelN-aryl-N′-methylbenzohydrazidesstructure-activity relationshiptoxicity
Identifiers
PMID41400363
PMCPMC12889028
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390